Edition:
United Kingdom

Aimmune Therapeutics Inc (AIMT.OQ)

AIMT.OQ on NASDAQ Stock Exchange Global Select Market

18.09USD
18 Jul 2019
Change (% chg)

-- (--)
Prev Close
$18.09
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
182,701
52-wk High
$36.12
52-wk Low
$16.97

Latest Key Developments (Source: Significant Developments)

European Phase 3 Trial Of Aimmune Therapeutics' AR101 Meets Primary Endpoint
Monday, 25 Mar 2019 

March 25 (Reuters) - Aimmune Therapeutics Inc ::EUROPEAN PHASE 3 TRIAL OF AIMMUNE THERAPEUTICS’ AR101 MEETS PRIMARY ENDPOINT.AIMMUNE THERAPEUTICS INC - INTENDS TO SUBMIT EUROPEAN MAA IN MID-2019.AIMMUNE THERAPEUTICS INC - SAFETY PROFILE AND COMPLETION RATE OBSERVED IN ARTEMIS ARE CONSISTENT WITH RESULTS SEEN IN PREVIOUS AR101 CLINICAL TRIALS.AIMMUNE THERAPEUTICS INC - NO CASES OF ANAPHYLAXIS OR OF EOSINOPHILIC ESOPHAGITIS (EOE) WERE OBSERVED.AIMMUNE THERAPEUTICS - PLANS TO PRESENT FULL RESULTS IN ORAL PRESENTATION AT EUROPEAN ACADEMY OF ALLERGY AND CLINICAL IMMUNOLOGY CONGRESS IN EARLY JUNE.  Full Article

Aimmune Therapeutics Announces Fourth Quarter Results
Thursday, 28 Feb 2019 

Feb 28 (Reuters) - Aimmune Therapeutics Inc ::AIMMUNE THERAPEUTICS ANNOUNCES FOURTH QUARTER AND FULL YEAR 2018 FINANCIAL RESULTS AND PROVIDES RECENT OPERATIONAL HIGHLIGHTS.Q4 LOSS PER SHARE $0.95.CASH, CASH EQUIVALENTS, & INVESTMENTS TOTALED $303.9 MILLION ON DEC 31, 2018, COMPARED TO $182.4 MILLION ON DEC 31, 2017.  Full Article

Aimmune Therapeutics Submits BLA To FDA For Ar101 For The Treatment Of Peanut Allergy In Children And Adolescents Ages 4–17
Friday, 21 Dec 2018 

Dec 21 (Reuters) - Aimmune Therapeutics Inc ::AIMMUNE THERAPEUTICS SUBMITS BLA TO FDA FOR AR101 FOR THE TREATMENT OF PEANUT ALLERGY IN CHILDREN AND ADOLESCENTS AGES 4–17.  Full Article

Nestle Health Science Us Holdings Inc Reports 18.9 Percent Stake In Aimmune Therapeutics As Of Nov 28
Monday, 3 Dec 2018 

Dec 3 (Reuters) - :NESTLE HEALTH SCIENCE US HOLDINGS, INC REPORTS 18.9 PERCENT STAKE IN AIMMUNE THERAPEUTICS INC AS OF NOV 28, 2018 - SEC FILING.NESTLE HEALTH SCIENCE US HOLDINGS, INC - HAD PREVIOSULY REPORTED 15.0 PERCENT STAKE IN AIMMUNE THERAPEUTICS INC AS OF FEB 26, 2018.  Full Article

Aimmune Therapeutics Qtrly Loss Per Share $0.89
Thursday, 8 Nov 2018 

Nov 8 (Reuters) - Aimmune Therapeutics Inc ::AIMMUNE THERAPEUTICS ANNOUNCES THIRD QUARTER 2018 FINANCIAL RESULTS AND RECENT CORPORATE HIGHLIGHTS.AIMMUNE THERAPEUTICS INC - AS OF SEPTEMBER 30, 2018, CASH, CASH EQUIVALENTS AND INVESTMENTS TOTALED $255.2 MILLION.AIMMUNE THERAPEUTICS INC QTRLY LOSS PER SHARE $0.89.  Full Article

Aimmune Therapeutics Reports Q1 Loss Per Share $0.92
Tuesday, 8 May 2018 

May 8 (Reuters) - Aimmune Therapeutics Inc ::AIMMUNE THERAPEUTICS ANNOUNCES FIRST QUARTER 2018 FINANCIAL RESULTS.Q1 LOSS PER SHARE $0.92.Q1 EARNINGS PER SHARE VIEW $-0.71 -- THOMSON REUTERS I/B/E/S.  Full Article

Aimmune Therapeutics Qtrly Loss Per Share $0.81
Monday, 12 Mar 2018 

March 12 (Reuters) - Aimmune Therapeutics Inc ::AIMMUNE THERAPEUTICS ANNOUNCES FOURTH QUARTER AND FULL YEAR 2017 FINANCIAL RESULTS.AIMMUNE THERAPEUTICS INC - QTRLY LOSS PER SHARE $0.81.AIMMUNE THERAPEUTICS INC - PLANNED BLA SUBMISSION ON TRACK FOR YEAR-END 2018.  Full Article

Aimmune Therapeutics Announces Pricing Of Public Offering Of Common Stock
Thursday, 22 Feb 2018 

Feb 21 (Reuters) - Aimmune Therapeutics Inc ::AIMMUNE THERAPEUTICS ANNOUNCES PRICING OF PUBLIC OFFERING OF COMMON STOCK.AIMMUNE THERAPEUTICS- ANNOUNCED ‍PRICING OF AN UNDERWRITTEN PUBLIC OFFERING OF 5.5 MILLION SHARES OF ITS COMMON STOCK AT A PRICE TO PUBLIC OF $32.00/SHARE​.  Full Article

Aimmune Therapeutics Announces Proposed Public Offering Of Common Stock
Tuesday, 20 Feb 2018 

Feb 20 (Reuters) - Aimmune Therapeutics Inc ::AIMMUNE THERAPEUTICS ANNOUNCES PROPOSED PUBLIC OFFERING OF COMMON STOCK.AIMMUNE THERAPEUTICS - COMMENCED OFFERING OF UP TO $150 MILLION SHARES.AIMMUNE - EXPECTS TO USE PROCEEDS FROM OFFERING TO FUND ONGOING CLINICAL DEVELOPMENT OF AR101.  Full Article

Aimmune Therapeutics' Phase 3 Palisade Trial Of Ar101 Meets Primary Endpoint In Patients With Peanut Allergy
Tuesday, 20 Feb 2018 

Feb 20 (Reuters) - Aimmune Therapeutics Inc ::AIMMUNE THERAPEUTICS’ PIVOTAL PHASE 3 PALISADE TRIAL OF AR101 MEETS PRIMARY ENDPOINT IN PATIENTS WITH PEANUT ALLERGY.AIMMUNE THERAPEUTICS’ PIVOTAL PHASE 3 PALISADE TRIAL OF AR101 MEETS PRIMARY ENDPOINT IN PATIENTS WITH PEANUT ALLERGY.AIMMUNE THERAPEUTICS-LOWER-BOUND OF 95% CONFIDENCE INTERVAL OF DIFFERENCE BETWEEN TREATMENT ARMS AT PRIMARY ENDPOINT WAS 53.0, GREATLY EXCEEDING PRE-SPECIFIED THRESHOLD OF 15%.AIMMUNE THERAPEUTICS-AMONG PATIENTS AGES 4-17 WHO COMPLETED TREATMENT WITH AR101, 96.3% TOLERATED A 300-MG DOSE OF PEANUT PROTEIN IN EXIT FOOD CHALLENGE.AIMMUNE THERAPEUTICS SAYS 2.4% OF AR101 PATIENTS AGES 4-17 AND 0.8% OF PLACEBO PATIENTS EXPERIENCED SERIOUS ADVERSE EVENTS.  Full Article